Results 101 to 110 of about 1,547 (116)

Three Years On: The Role of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) since Its Initial Approval

International Journal of Molecular Sciences
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease characterized by complement-mediated hemolysis and potentially life-threatening complications.
Regina Horneff, Michael Yeh
exaly   +2 more sources

Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison

Current Medical Research and Opinion, 2021
In the absence of a head-to-head study, we assessed the comparative effectiveness of pegcetacoplan, a targeted C3 complement inhibitor, vs. ravulizumab, a C5 complement inhibitor, among patients with paroxysmal nocturnal hemoglobinuria (PNH) previously ...
Mei Sheng Duh, Sanjana Sundaresan
exaly   +2 more sources

Occlusive Retinal Vasculitis After a Single Injection of Pegcetacoplan

Journal of Vitreoretinal Diseases
Purpose: To describe a patient with retinal vasculitis after a single intravitreal injection (IVI) of pegcetacoplan. Methods: A case and its findings were analyzed.
Janet Davis
exaly   +2 more sources

Efficacy of complement inhibition with pegcetacoplan in children with C3 glomerulopathy

Pediatric Nephrology
Background: C3 glomerulopathy (C3G) is a rare kidney disease due to a dysregulation of the alternative complement pathway, orphan of specific treatment.
Antonio Mastrangelo, Gianluigi Ardissino, Giovanni Montini   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria

Clinical and Experimental Medicine, 2022
Bo Xu
exaly  

Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases

Kidney International Reports, 2023
Larry Greenbaum, Bradley Dixon
exaly  

Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors

International Journal of Molecular Sciences
Peter Hillmen, Martin Kolev, Pascal Deschatelets   +2 more
exaly  

Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria

Expert Review of Hematology
Yeow Tee Goh
exaly